Company Overview - Alphatec Holdings specializes in advanced spinal surgery systems, including neural monitoring, fixation, and implant technologies, as well as biologics and imaging products [7][8] - The company generates revenue primarily through the direct sale and distribution of proprietary medical devices and surgical solutions for spinal disorder treatments, targeting hospitals, surgeons, and healthcare providers in the U.S. [7][8] - For the trailing twelve months (TTM), Alphatec reported revenue of $728.02 million and a net income loss of $154.96 million [4] Recent Insider Activity - Scott Lish, the Chief Operating Officer, sold 19,900 shares for approximately $390,836 on December 16, 2025, which represents a 3.01% decrease in his direct holdings, leaving him with 641,432 shares post-sale [1][2][6] - The sale aligns with Lish's median trade size and reflects a consistent selling pattern amid strong share price appreciation [6] Market Performance - Alphatec's shares experienced a 127.08% price change over the past year, with a notable total return of 108.7% [4][6] - The stock reached a 52-week high of $22.66 on November 26, significantly up from a low of $8.81 in April [10] - The company's third-quarter revenue of $197 million marked a 30% year-over-year increase, with a gross margin of 70% [11] Investment Considerations - Despite the insider selling, the transaction does not raise concerns as Lish retains a substantial number of shares [9] - The current price-to-sales ratio of over four indicates a favorable market environment for selling shares, especially given the company's trajectory towards profitability [10][11] - Investors are advised to consider waiting for a potential drop in share price before making new investments in Alphatec [12]